Image from Google Jackets

The clozapine handbook

By:

Meyer, Jonathan M

Contributor(s):

Stahl, Stephen M

Series: Stahl's handbooks | Cambridge medicinePublication details: Cambridge : Cambridge University Press, 2019.Description: xi, 317pISBN:

9781108447461

Subject(s):

NLM classification:

WM 402.

Contents:

Preface 1. Initiating Clozapine 2. Understanding hematologic monitoring and benign ethnic neutropenia 3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels 4. Managing constipation 5. Managing sialorrhea 6. Managing sedation, orthostasis and tachycardia 7. Managing metabolic adverse effects 8. Managing seizure risk and stuttering 9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy 10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities 11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder 12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients 14. Discontinuing clozapine and management of cholinergic rebound 15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution Index.

Summary: Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

Holdings
Item type	Home library	Class number	Status	Barcode
Book	Oxleas NHS Foundation Trust Knowledge Services Librarians Office	WM 402 MEY (Browse shelf(Opens below))	Available	x02081
Book	Oxleas NHS Foundation Trust Knowledge Services Librarians Office	WM 402 MEY (Browse shelf(Opens below))	Available	x02083
Book	Oxleas NHS Foundation Trust Knowledge Services Librarians Office	WM 402 MEY (Browse shelf(Opens below))	Available	x02082
Book	South London and Maudsley Trust Library Shelves	WM 402 MEY (Browse shelf(Opens below))	Available	023415
Book	South London and Maudsley Trust Library Shelves	WM 402 MEY (Browse shelf(Opens below))	Available	023390

Browsing Oxleas NHS Foundation Trust Knowledge Services shelves, Shelving location: Librarians Office Close shelf browser (Hides shelf browser)

Previous
Previous	WM 20 Critical appraisal for psychiatry	WM 402 MEY The clozapine handbook	WM 402 MEY The clozapine handbook	WM 402 MEY The clozapine handbook

Preface
1. Initiating Clozapine
2. Understanding hematologic monitoring and benign ethnic neutropenia
3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels
4. Managing constipation
5. Managing sialorrhea
6. Managing sedation, orthostasis and tachycardia
7. Managing metabolic adverse effects
8. Managing seizure risk and stuttering
9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy
10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities
11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder
12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis
13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients
14. Discontinuing clozapine and management of cholinergic rebound
15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution
Index.

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

There are no comments on this title.

to post a comment.